{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004193","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.677675+00:00","generated_at":"2026-06-20T17:37:36.248212+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiMedx reaffirms Q4/FY2022 sales; warns of Medicare reimbursement risk for skin substitutes","bullets":["Q4 2022 net sales expected $73M-$76M; FY2022 $266M-$269M, unchanged from Nov 2022 guidance.","About 28% of 2022 sales from private physician office; ~75% of that reimbursed by CMS, over 90% is EPIFIX.","Received FDA TRG letter confirming EPIFIX as Section 361 product in Dec 2022; seeking confirmation for EPICORD.","Restructuring headcount reductions expected to cut annualized costs by ~$5M; sales force realigned for productivity.","Entered distribution partnership with Gunze Medical for EPIFIX in Japan; appointed Ricci Whitlow as COO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004193","json":"https://secwatch.observer/filing/0001193125-23-004193.json","markdown":"https://secwatch.observer/filing/0001193125-23-004193.md","text":"https://secwatch.observer/filing/0001193125-23-004193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000119312523004193/0001193125-23-004193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000119312523004193/d442188d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:37:36.248212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e73d010025cdb2de3c763e15ee7d097fea8c9c0a","claim":"MIMEDX GROUP, INC. updated its fourth quarter of 2022 and full year 2022 guidance (reaffirmed).","evidence_excerpt":"reaffirming its fourth quarter of 2022 and full year 2022 net sales expectations.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1376339/000119312523004193/0001193125-23-004193-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter of 2022 and full year 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}